Greene, CM; Marciniak, SJ; Teckman, J; Ferrarotti, I; Brantly, ML; Lomas, DA; Stoller, JK; Greene, CM; Marciniak, SJ; Teckman, J; Ferrarotti, I; Brantly, ML; Lomas, DA; Stoller, JK; McElvaney, NG; - view fewer (2016) α1-Antitrypsin deficiency. Nature Reviews Disease Primers , 2 , Article 16051. 10.1038/nrdp.2016.51.

Preview

Text Lomas_Author Correction. α1-Antitrypsin deficiency_AAM.pdf - Accepted Version Download (1MB) | Preview

Abstract

1-Antitrypsin deficiency (A1ATD) is an inherited disorder caused by mutations in SERPINA1, leading to liver and lung disease. It is not a rare disorder but frequently goes underdiagnosed or misdiagnosed as asthma, chronic obstructive pulmonary disease (COPD) or cryptogenic liver disease. The most frequent disease-associated mutations include the S allele and the Z allele of SERPINA1, which lead to the accumulation of misfolded α1-antitrypsin in hepatocytes, endoplasmic reticulum stress, low circulating levels of α1-antitrypsin and liver disease. Currently, there is no cure for severe liver disease and the only management option is liver transplantation when liver failure is life-threatening. A1ATD-associated lung disease predominately occurs in adults and is caused principally by inadequate protease inhibition. Treatment of A1ATD-associated lung disease includes standard therapies that are also used for the treatment of COPD, in addition to the use of augmentation therapy (that is, infusions of human plasma-derived, purified α1-antitrypsin). New therapies that target the misfolded α1-antitrypsin or attempt to correct the underlying genetic mutation are currently under development.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item